CSIMarket Company Name, Ticker, Competitors, else..
 
Curevac N v   (NASDAQ: CVAC)
Other Ticker:  
 
 
Price: $3.1700 $-0.02 -0.627%
Day's High: $3.32 Week Perf: -0.63 %
Day's Low: $ 3.13 30 Day Perf: 4.28 %
Volume (M): 487 52 Wk High: $ 5.28
Volume (M$): $ 1,543 52 Wk Avg: $3.25
Open: $3.25 52 Wk Low: $2.22



 Market Capitalization (Millions $) 700
 Shares Outstanding (Millions) 221
 Employees 370
 Revenues (TTM) (Millions $) 60
 Net Income (TTM) (Millions $) -291
 Cash Flow (TTM) (Millions $) 555
 Capital Exp. (TTM) (Millions $) 59

Curevac N V
CureVac N.V. is a German biotechnology company that focuses on the development of mRNA-based vaccines and therapeutics. The company was founded in 2000 by Ingmar Hoerr, Steve Pascolo, and Florian von der Muelbe.

CureVac's main area of expertise lies in the field of messenger RNA (mRNA) technology, which involves using mRNA molecules to instruct cells to produce specific proteins. This technology has the potential to revolutionize the field of medicine by enabling the development of highly targeted and personalized treatments for various diseases.

CureVac has developed a portfolio of candidate vaccines for diseases such as COVID-19, influenza, rabies, and Zika. The company's most notable achievement has been the development of a COVID-19 vaccine, which has shown promising results in clinical trials.

In addition to vaccines, CureVac is also working on the development of mRNA-based therapies for cancer, rare diseases, and other conditions. The company has collaborated with various pharmaceutical companies and research institutions to advance its pipeline of products.

CureVac went public in 2020 and is listed on the Nasdaq under the ticker symbol CVAC. The company has attracted significant attention and investment due to its innovative mRNA technology and the potential of its products to transform healthcare.


   Company Address: Friedrich-Miescher-Strasse 15 Tübingen 72076
   Company Phone Number:    Stock Exchange / Ticker: NASDAQ CVAC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY      % 
DVAX      % 
EBS      % 
OPK      % 
PFE      % 
REGN        6.13% 
• View Complete Report
   



Unity Biotechnology Inc

The Major Pharmaceutical Preparations company added some great scenario for the investors, presenting a relevant growth in January to March 31 2025 with operating shortfall of $-6.891 million

The investors have not assumed any adjustments at the revenue throughout the the January to March 31 2025 reporting cycle at the UBX. But, they pay very near attention to the company's operating shortfall which came in at $-6.891 million, in the same period.

Bioadaptives Inc

Observing the fourth quarter of 2024 results, the company's saw top-line has dropped by -88.085 %

For the fiscal fourth quarter of 2024 company reached break-even of $0.00 per share compare to $0.00 a year before and from $0.00 per share from the previous reporting period. The revenue fell sharply to $0.00 million from $0.01 million in the same reporting period a year before and sequentially from $0.00 million.

Transcode Therapeutics Inc

The Major Pharmaceutical Preparations company published operating loss of $-5.092387 million, in the October to December 31 2024 time-frame

While the October to December 31 2024 reporting cycle resumes, many companies have reported the respective earnings. In the thick of it, have been various entities in the Major Pharmaceutical Preparations sector. As well as, now, Transcode Therapeutics Inc reported operating loss of $-5.092387 million, for the October to December 31 2024 time-frame.

Eyenovia Inc

The Deficit has widen more at the Major Pharmaceutical Preparations company amid the October to December 31 2024 financial time-frame

Eyenovia Inc announced very solid Revenue rise year on year to $0.03 million in the October to December 31 2024 span, but increased a deficit per share at $-59.26.

Vaccinex Inc

The company announced Revenue of $0.199 million, in the fiscal interval ending December 31 2024

Vaccinex Inc has seen $0.199 million, in Revenue in the fourth quarter of 2024.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com